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Objectives The aim of this study was to investigate whether the reported favorable 1-year outcome of the sirolimus-eluting
stent (SES) versus the bare-metal stent (BMS) in the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In
Acute Myocardial Infarction) trial, in the setting of ST-segment elevation myocardial infarction (STEMI), is main-
tained at 3-year follow-up.
Background At present, only long-term registry data, but not randomized trials, on the safety and effectiveness of SES in
STEMI patients are available.
Methods Overall, 320 STEMI patients were randomized to receive SES or BMS. The primary end point was the incidence
of major adverse cardiovascular events (MACE), at 3-year follow-up. The secondary end points were the rate of
target lesion revascularization (TLR) and target vessel revascularization (TVR) and target vessel failure (TVF).
The incidence of late events, starting from clopidogrel withdrawal, was also investigated.
Results The 3-year incidence of MACE was lower in the SES group compared with the BMS group (12.7% vs. 21%,
p  0.034), as were TLR (7% vs. 13.5%, p  0.048), TVR (8% vs. 16%, p  0.027), and TVF (11.5% vs. 20.5%,
p  0.028) rates. The 3-year survival rate free from MACE, TLR, and TVF was significantly higher in the SES
group than in the BMS group (87%, 93%, and 89.5% vs. 79%, 86.5%, and 79.5%, respectively, p  0.05). The
lower incidence of adverse events in the SES group was driven by TLR reduction and achieved in the first year of
follow-up. The cumulative incidence of death and recurrent myocardial infarction, starting from clopidogrel dis-
continuation, was comparable in the 2 groups.
Conclusions The clinical benefits of SES have been shown to be greater than those of BMS at 3-year follow-up. (J Am Coll
Cardiol 2010;55:810–4) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.046r
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crimary percutaneous coronary intervention (PCI) has be-
ome the treatment of choice in patients presenting with
T-segment elevation myocardial infarction (STEMI) (1).
rug-eluting stents (DES) effectively reduce neointimal
roliferation with better short- and long-term clinical and
ngiographic results, and these are as safe as bare-metal
tents (BMS) (2–4). However, concerns have been raised
egarding the long-term safety and effectiveness of DES
mplantation in the setting of STEMI (5). Long-term
rom the *Interventional Cardiology Department, San Camillo Hospital, Rome,
taly; and the †Campus Bio-Medico University, Rome, Italy.c
Manuscript received May 2, 2009; revised manuscript received September 9, 2009,
ccepted September 14, 2009.andomized data in this subgroup of patients have usually
een limited to 2 years (6–8). The aim of the present
nalysis was to define whether the favorable effect on clinical
utcome, observed in the SESAMI (Sirolimus-Eluting
tent Versus Bare-Metal Stent In Acute Myocardial Infarc-
ion) trial (7), persisted at 3 years’ follow-up.
ethods
atient selection. The design and detailed methods of the
ESAMI trial have been published elsewhere (7).
tudy end points and definitions. The primary end point
f this trial was the incidence of major adverse cardiovas-
ular events (MACE) at 3-year follow-up, defined as a
omposite of cardiac and noncardiac death, Q-wave and
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February 23, 2010:810–4 3-Year Outcome of the SESAMI Trialon–Q-wave myocardial infarction (MI), coronary artery
ypass grafting (CABG), or target lesion revascularization
TLR). The secondary end points were: 1) 3-year TLR,
efined as repeated PCI or CABG of the target lesion
riven by clinical symptoms of myocardial ische-
ia, a positive stress test due to the target vessel, or in-stent
estenosis 70% of the reference luminal diameter; 2) 3-year
arget vessel revascularization (TVR), defined as repeated
evascularization within the treated vessel; and 3) 3-year
arget vessel failure (TVF), defined as a combination of
VR, recurrent MI, and target vessel-related death.
Stent thrombosis (ST) was classified according to the
efinitions of the Academic Research Consortium (9).
The cumulative incidence of death from all causes and
ecurrent MI, starting from dual antiplatelet therapy dis-
ontinuation, was also recorded.
ollow-up protocol. Patients were scheduled to undergo
linical follow-up at 30 days and thereafter at 6, 12, 24,
nd 36 months. An independent clinical-event commit-
ee, the members of which were unaware of the patient’s
reatment, reviewed all clinical end points during
ollow-up.
tatistical analysis. The comparison between variables
epresenting counts was assessed with the chi-square test or
isher exact test. Normally distributed variables were as-
essed with Student t test. The TLR and the composite of
ACE and TVF were analyzed by the Kaplan-Meier
ethod, and survival between groups was compared with
he log-rank test. A 2-sided probability value of p  0.05
as considered statistically significant.
esults
aseline characteristics. Baseline characteristics and pro-
edural results of patients are shown in Table 1.
ong-term clinical follow-up. Complete datasets were
vailable in 157 of 160 (98%) patients in the SES group and
n 156 of 160 (97.5%) patients in the BMS group.
The 3-year outcome is outlined in Table 2. The SES
mplantation showed a reduction of 40.5% in MACE risk
ompared with BMS (12.7% vs. 21%, p  0.034). The
umulative 3-year survival rates free from MACE were 87%
nd 79% for the SES group and the BMS group, respec-
ively (p  0.05) (Fig. 1A). Results of the SES were, with
egard to concerns overall secondary end points, better than
hose of BMS: TLR 7% versus 13.5% (p 0.048) with 48%
f risk reduction; TVR 8% versus 16% (p  0.027) with
0% of risk reduction; and TVF 11.5% versus 20.5% (p 
.028) with 44% of risk reduction. The lower incidence of
dverse events in the SES group was due primarily to fewer
LRs. The greatest benefit was achieved in the first year
f follow-up with no significant differences between 12
nd 36 months. The cumulative 3-year survival rates free
rom TLR (Fig. 1B) and TVF (Fig. 1C) were 93% and
9.5% for the SES group and 86.5% and 79.5% for the
MS group, respectively (p  0.05). There was no itatistical difference in terms of
eath, recurrent MI, or ST be-
ween the 2 groups.
We revealed, compared with
he previous assessment of clin-
cal outcome at 1-year, 12 new
ACE, 7 in the SES group
Table 3). In this group 2 more
atients died—1 from gastric
ancer, and 1 from pulmonary
mbolism. One patient presented
ith nonfatal recurrent MI, and
patients underwent TLR—3
nderwent re-PCI for a focal
n-stent restenosis in 2 cases and
T in 1 case. The fourth patient
nderwent CABG for in-stent
estenosis and progression of
he left main coronary artery
isease. In the BMS group, an-
ther patient died from lung
ancer, and another had nonfa-
al MI. Another 3 patients underwent percutaneous
LR—1 for focal in-stent restenosis, 1 for diffuse in-
tent restenosis, and 1 for ST.
The mean duration of dual antiplatelet therapy was 375 12
ays and 369  35 days for the SES and BMS groups,
espectively (p  NS). The cumulative incidence of death
or all causes and nonfatal MI was comparable in the 2
roups starting from the time of clopidogrel discontinuation
t 3-year follow-up.
aseline and Proceduralharacteristics f the SES and BMS GroupTable 1 Baseline and ProceduralCharacteristics of the SES and BMS Group
SES Group BMS Group p Value
Baseline characteristics
n 160 160
Age, yrs 63 (54–70) 62 (52–72) 0.81
Male sex 128 (80) 128 (80)
Diabetes mellitus 28 (17.5) 37 (23.7) 0.13
Hypertension 87 (54.3) 98 (58.7) 0.20
Hyperlipidemia 123 (62.5) 105 (65%) 0.12
Smoker 91 (56.8) 83 (51.7) 0.1
Prior myocardial infarction 9 (5.6) 20 (12.5) 0.047
Prior PCI 15 (9.4) 17 (10.6%) 0.38
Time from symptom onset to PCI 4 (3–7) 4 (3–6) 0.64
DAT, days 375 12 369 35 NS
Procedural characteristics
PCI rescue 28 (17.5) 29 (18.2) 0.54
Abciximab therapy 124 (77.5) 118 (74%) NS
Stent length, mm 19.4 4.8 16.9 4.1 0.001
Stent diameter, mm 3.02 0.28 3.14 0.034 0.001
alues are n, mean (range), n (%), or mean  SD.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
MACE  major adverse
cardiovascular event
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularizationBMS  bare-metal stent(s); DAT  dual antiplatelet tre
ntervention; SES  sirolimus-eluting stent(s).atment; PCI  percutaneous coronary
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3-Year Outcome of the SESAMI Trial February 23, 2010:810–4iscussion
he present study demonstrates that SES implantation is
etter, in terms of MACE, TLR, TVR, and TVF, com-
ared with BMS in patients with STEMI at 3-year follow-
p. The greatest benefit was achieved in the first year and
aintained at 3 years.
The main proven benefit of DES versus BMS is the
eduction of restenosis in various clinical and angiographic
ettings (10), especially in high-risk patients such as those
resenting with STEMI (6–8,11). Restenosis is not a
enign clinical occurrence, because it has been associated
ith increased risk of death and MI (12). However, ran-
omized data on long-term safety and efficacy of DES in
he STEMI setting are still lacking. In the STRATEGY
Single High Dose Bolus Tirofiban and Sirolimus Eluting
tent vs Abciximab and Bare Metal Stent in Myocardial
nfarction) trial (7) it has been demonstrated that the
umulative incidence of MACE was constantly lower in the
irofiban  SES group compared with Abciximab  BMS
roup due primarily to the different rate of TVR without
ny significant increase in the death rate, recurrent MI, or
T at 2-year clinical follow-up. Our study confirms these
ndings and extends the clinical follow-up to 3 years. The
ES treatment was associated with a 40.5% risk reduction of
ACE with a cumulative incidence of MACE-free survival
f 87% compared with 79% in the BMS group, even if the
ES group had longer and smaller implanted stents. In
greement with our results, a recent meta-analysis of ran-
omized trials comparing the short- and the long-term
linical benefit of SES versus BMS showed a significant
eduction in TVR with no significant difference in ST
ncidence in SES patients at 1-, 2-, and 3-year follow-up
13). In contrast to our results, a recent nonrandomized
tudy, comparing 3-year clinical outcome of SES,
aclitaxel-eluting stent, and BMS in patients with STEMI,
howed that SES was more efficacious in triggering a
ecrease in TVR compared with paclitaxel-eluting stent or
MS only at 1-year follow-up. This advantage was lost at
linical Outcome at 3 YearsTable 2 Clinical Outcome at 3 Years
SES Group BMS Group p Value
n 157 156
Death 5 (3.2) (1–7.2) 8 (5) (2.2–10) 0.38
Reinfarction 4 (2.5) (0.7–6.3) 4 (2.5) (0.7–6.4) NS
Stent thrombosis
Definite 3 (1.9) (0.4–5.4) 2 (1.3) (0.1–4.5) NS
Probable/possible 5 (3.2) (1–7.2) 6 (3.8) (1.4–8.1) NS
MACE 20 (12.7) (8–18) 33 (21) (15–28) 0.034
TLR 11 (7) (3.5–12) 21 (13.5) (8.5–19) 0.048
TVR 13 (8.3) (4–13) 25 (16) (10–22) 0.027
TVF 18 (11.5) (7–17) 32 (20.5) (14–27) 0.028
alues are n (%) (95% confidence interval).
MACEmajor adverse cardiovascular event; TLR target lesion revascularization; TVF target
essel failure; TVR  target vessel revascularization; other abbreviations as in Table 1.-year follow-up, partly explained by the occurrence of lateT in the SES group (14). In a recent multinational registry
f patients with STEMI, who had undergone PCI with
ES or BMS, a similar mortality was reported for the first
months after discharge but was significantly higher from 6
onths to 2 years for DES patients, compared with BMS
atients (15). Indeed, primary stenting has been recognized
s an independent predictor of late stent malapposition in
MS (16) as well as in DES patients (17), with an incidence
- to 3-fold higher compared with elective stenting. Poten-
ial mechanisms of late adverse events are still controversial.
hrombus displacement by the stent struts with abluminal
hrombus resolution in the long-term might lead to a major
ncidence of stent malapposition and might account for the
Figure 1 Actuarial Rates of Survival
Free From MACE, TLR, and TVR
Kaplan-Meier estimates of survival free from major adverse cardiovascular
events (MACE) (A), target lesion revascularization (TLR) (B), and target vessel
failure (TVF) (C) among patients treated with a sirolimus-eluting stent (SES) or
bare-metal stent (BMS). The MACE, TLR and TVF free survival was significantly
higher in the SES group than the BMS group (p  0.05).
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February 23, 2010:810–4 3-Year Outcome of the SESAMI Trialigher rates of early and late ST (18). Moreover, a large
hrombus burden can affect stent-based drug-elution and
ignificantly alter vessel wall drug levels and potentially the
fficacy, thus explaining the higher rate of in-stent restenosis
n patients with STEMI compared with that in those with
ther clinical settings (19). By contrast, recent data suggest
hat late adverse events are caused mainly by a ruptured
laque in the adjacent vessel outside the stent and are not
trictly stent-related (20,21). Another risk factor for late
dverse events seems to be premature discontinuation of
ual antiplatelet therapy (22). In a large observational
tudy, DES ST was observed in approximately 30% of
atients who prematurely discontinued antiplatelet ther-
py (23). Much controversy still exists concerning the
uration of dual antiplatelet therapy in STEMI patients.
ome authors concluded that, because the cardiovascular
utcomes improved with more robust or prolonged anti-
latelet therapy in patients with acute coronary syn-
romes or prior history of ischemic events or PCI, it
hould be recommended for 1 year—perhaps indefi-
itely—in all patients receiving DES (24).
In contrast with these findings, in our study, the rate of
efinite ST was 1.9% in the SES group and 1.3% in the
MS group (p  NS), whereas the cumulative incidence of
eath and nonfatal recurrent MI was comparable in the 2
roups starting from the time of clopidogrel discontinua-
ion. In agreement with our data it has been reported that,
lthough withdrawal of clopidogrel was associated with an
ncreased mortality risk, it does not depend upon the type of
tent implanted (25). Moreover, a recent collaborative net-
ork meta-analysis (26) focused on safety and effectiveness
f DES and BMS in high-risk patients such as those with
iabetes mellitus. Results suggested that the previously
eported increased risk of death, associated with SES, was
robably due to the short duration of dual antiplatelet
herapy in early studies but was no longer found in trials in
hich dual antiplatelet therapy was given for 6 months.
tudy limitations. First, this 3-year follow-up study is
linical Events During 12- to 36-Month Follow-UpTable 3 Clinical Events During 12- to 36-Month Follow-Up
SES Group BMS Group p Value
n 144 127
Death 2 (1.4) (0.1–4) 1 (0.8) (0.01–4.3) NS
Reinfarction 1 (0.7) (0.01–3) 1 (0.8) (0.01–4.3) NS
Stent thrombosis
Definite 1 (0.7) (0.01–3) 1 (0.8) (0.01–4.3) NS
Probable/possible 0 0 NS
MACE 7 (4.8) (1.9–9) 5 (3.9) (1.2–8.9) NS
TLR 4 (2.7) (0.7–6.9) 3 (2.3) (0.4–6.7) NS
TVR 6 (4.1) (1.5–8.8) 7 (5.5) (2.2–11) NS
TVF 7 (4.8) (1.9–9.7) 8 (6.3) (2.7–12) NS
Death/re-MI 3 (2) (0.4–5.9) 2 (1.5) (0.1–5.5) NS
alues are n (%) (95% confidence interval).
MI  myocardial infarction; other abbreviations as in Tables 1 and 2.imited to clinical end points. Second, although no differ-nces were found in terms of incidence of death, recurrent
I, and ST at 3-year follow-up or in MACE during 12- to
6-month follow-up, the study does not have sufficient
ower to demonstrate significant differences in these adverse
linical events.
onclusions
he present study demonstrates that SES are associated
ith a significant reduction of MACE, TLR, TVR, and
VF compared with BMS at 3-year follow-up after stenting
or STEMI. The SES seems to be as safe as BMS, without
vidence of any increased risk of death, recurrent MI, or ST,
ncluding no incremental risks after withdrawal of dual
ntiplatelet therapy.
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